{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T12:59:18Z","timestamp":1792760358589,"version":"4.5.0"},"reference-count":11,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["international-journal-of-gynecological-cancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Gynecological Cancer"],"published-print":{"date-parts":[[2026,2]]},"DOI":"10.1016\/j.ijgc.2025.102779","type":"journal-article","created":{"date-parts":[[2025,11,8]],"date-time":"2025-11-08T16:09:11Z","timestamp":1762618151000},"page":"102779","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"title":["Folate receptor alpha as a successful biomarker in the treatment of low-grade serous ovarian cancer patients using preclinical and clinical models"],"prefix":"10.1016","volume":"36","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2439-2534","authenticated-orcid":false,"given":"Victoria M.","family":"Ettorre","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-2737-799X","authenticated-orcid":false,"given":"Beatrice","family":"Conca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cem","family":"Demirkiran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5909-5292","authenticated-orcid":false,"given":"Stefania","family":"Bellone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1586-3338","authenticated-orcid":false,"given":"Namrata","family":"Sethi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tobias Max Philipp","family":"Hartwich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1016-7851","authenticated-orcid":false,"given":"Na","family":"Niu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natalia","family":"Buza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberto","family":"Angioli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Plotti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9704-3300","authenticated-orcid":false,"given":"Luca","family":"Palmieri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandro D.","family":"Santin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.ijgc.2025.102779_bib1","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1097\/01.pgp.0000101080.35393.16","article-title":"The histologic type and stage distribution of ovarian carcinomas of surface epithelial origin","volume":"23","author":"Seidman","year":"2004","journal-title":"Int J Gynecol Pathol"},{"issue":"2","key":"10.1016\/j.ijgc.2025.102779_bib2","doi-asserted-by":"crossref","first-page":"458","DOI":"10.3390\/diagnostics12020458","article-title":"Low-grade serous carcinoma of the ovary: the current status","volume":"12","author":"Babaier","year":"2022","journal-title":"Diagnostics (Basel)"},{"issue":"10324","key":"10.1016\/j.ijgc.2025.102779_bib3","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1016\/S0140-6736(21)02175-9","article-title":"Trametinib versus standard of care in patients with recurrent low-grade serous ovarian cancer (GOG 281\/LOGS): an international, randomised, open-label, multicentre, phase 2\/3 trial","volume":"399","author":"Gershenson","year":"2022","journal-title":"Lancet"},{"key":"10.1016\/j.ijgc.2025.102779_bib4","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/j.ygyno.2024.06.008","article-title":"Folate receptor alpha expression in low-grade serous ovarian cancer: exploring new therapeutic possibilities","volume":"188","author":"Manning-Geist","year":"2024","journal-title":"Gynecol Oncol"},{"issue":"23","key":"10.1016\/j.ijgc.2025.102779_bib5","doi-asserted-by":"crossref","first-page":"2162","DOI":"10.1056\/NEJMoa2309169","article-title":"Mirvetuximab soravtansine in FRalpha-positive, platinum-resistant ovarian cancer","volume":"389","author":"Moore","year":"2023","journal-title":"N Engl J Med."},{"key":"10.1016\/j.ijgc.2025.102779_bib6","series-title":"VENTANA\u00ae FOLR1 (FOLR1-2.1) RxDx Assay","author":"Roche","year":"2025"},{"issue":"5","key":"10.1016\/j.ijgc.2025.102779_bib7","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1158\/1535-7163.MCT-17-0930","article-title":"In vitro and in vivo activity of IMGN853, an antibody-drug conjugate targeting folate receptor alpha linked to DM4, in biologically aggressive endometrial cancers","volume":"17","author":"Altwerger","year":"2018","journal-title":"Mol Cancer Ther"},{"key":"10.1016\/j.ijgc.2025.102779_bib11","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1097\/PGP.0000000000001053","article-title":"Folate receptor immunohistochemical staining and gynecologic tumors: Initial experience with 216 cases","volume":"44","author":"Lawson","year":"2025","journal-title":"Int J Gynecol Pathol"},{"key":"10.1016\/j.ijgc.2025.102779_bib8","doi-asserted-by":"crossref","DOI":"10.14694\/EdBook_AM.2013.33.e195","article-title":"The life and times of low-grade serous carcinoma of the ovary","volume":"33","author":"Gershenson","year":"2013","journal-title":"Am Soc Clin Oncol Educ Book"},{"issue":"5","key":"10.1016\/j.ijgc.2025.102779_bib9","doi-asserted-by":"crossref","first-page":"e74","DOI":"10.3802\/jgo.2025.36.e74","article-title":"FOLR1 as a therapeutic target in platinum-resistant ovarian carcinoma: unique expression patterns across ovarian carcinoma histotypes and molecular subtypes of low-grade serous carcinoma","volume":"36","author":"Leung","year":"2025","journal-title":"J Gynecol Oncol"},{"issue":"10","key":"10.1016\/j.ijgc.2025.102779_bib10","doi-asserted-by":"crossref","first-page":"930","DOI":"10.5858\/arpa.2024-0210-OA","article-title":"Evaluation of Laboratory-Derived immunohistochemical Assays for Folate Receptor alpha Expression in Epithelial Ovarian Cancer and Comparison with a Companion Diagnostic","volume":"149","author":"Deutschman","year":"2025","journal-title":"Arch Pathol Lab Med"}],"container-title":["International Journal of Gynecological Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1048891X25019012?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1048891X25019012?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,28]],"date-time":"2026-05-28T21:19:33Z","timestamp":1780003173000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1048891X25019012"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2]]},"references-count":11,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,2]]}},"alternative-id":["S1048891X25019012"],"URL":"https:\/\/doi.org\/10.1016\/j.ijgc.2025.102779","relation":{},"ISSN":["1048-891X"],"issn-type":[{"value":"1048-891X","type":"print"}],"subject":[],"published":{"date-parts":[[2026,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Folate receptor alpha as a successful biomarker in the treatment of low-grade serous ovarian cancer patients using preclinical and clinical models","name":"articletitle","label":"Article Title"},{"value":"International Journal of Gynecological Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijgc.2025.102779","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 European Society of Gynaecological Oncology and the International Gynecologic Cancer Society. Published by Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"102779"}}